Tremendous innovation is underway among a rapidly expanding repertoire of promising
personalized immune-based treatments. Therapeutic cancer vaccines (TCVs) are attractive …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

Vaccines are an important tool in the rapidly evolving repertoire of immunotherapies in
oncology. Although cancer vaccines have been investigated for over 30 years, very few …

Background: Cancer vaccines are a unique approach to cancer therapy. They exert an
antitumor effect by engaging the host immune response, and have great potential for …

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …

The development of cancer vaccines has been intensively pursued over the past 50 years
with modest success. However, recent advancements in the fields of genetics, molecular …

There are strong biologic and preclinical rationales for the development of therapeutic
cancer vaccines; however, the clinical translation of this treatment strategy has been …

After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …

Treating cancer with vaccines has been a challenging field of investigation since the 1950s.
Over the years, the lack of effective active immunotherapies has led to the development of …

In recent years, there has been a surge of interest in tumor microenvironment-associated
cancer vaccine therapies. These innovative treatments aim to activate and enhance the …